Mannose-6-Phosphate/Insulin-Like Growth Factor 2 Receptor (M6P/IGF2-R) in Growth and Disease: A Review by Lemamy, Guy Joseph et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Mannose-6-Phosphate/Insulin-Like Growth Factor 2
Receptor (M6P/IGF2-R) in Growth and Disease: A
Review
Guy Joseph Lemamy, Bénédicte Ndeboko,
Serge Thierry Omouessi and Justine Mouecoucou
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64810
Provisional chapter
i  t  act r 2
 ( I - ) in Growth and Disease: A Review
Guy Joseph Lemamy, Bénédicte Ndeboko,
Serge Thierry Omouessi and Justine Mouecoucou
Additional information is available at the end of the chapter
Abstract
This work aims to summarize the current knowledge about Mannose-6- Phosphate/
Insulin-like Growth Factor 2 Receptor (M6P/IGF2-R) in the regulation of growth and
development,  and  its  involvement  in  tumor  progression.  M6P/IGF2-R  binds  both
molecules sharing M6P signals and IGF2.  The studies showed that  M6P/IGF2-R is
involved in the trafficking of mannnose-6-phosphorylated enzymes from the Trans-
Golgi Network (TGN) to lysosomes and the uptake of secreted proenzymes from the
plasma membrane to the lysosomes via clathrin-coated vesicles for their maturation.
The M6P/IGF2-R acts as a scavenger that binds IGF2 and transports it to lysosomes for
its  degradation  since  IGF2  exerts  its  biological  effects  on  cell  proliferation  and
development by binding with lower affinity on IGF1 receptor, which is structurally
similar to insulin receptor and different from the M6P/IGF2-R. The M6P/IGF2-R has also
been studied in human cancer, and frequent losses of heterozygosity (LOH) at the
6q25-27 gene region with mutations in the remaining allele have been described. These
results led to consider M6P/IGF2-R gene as a putative tumor suppressor and its potential
prognostic value has been suggested.
Keywords: M6P/IGF2-R, genomic imprinting, cell growth and development, loss of
heterozygosity (LOH), human cancer, tumor suppressor
1. Introduction
Two mannose-6-phosphate receptors (M6PRs) have been described: the mannose-6-phos-
phate/insulin-like growth factor 2 receptor (M6P/IGF2-R) binds both M6P ligands and IGF2
[1, 2] and the cation-dependent mannose-6-phosphate receptor (CD-M6PR), which needs
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divalent cations to bind M6P ligands but does not bind insulin-like growth factor 2 [3]. The
M6P/IGF2-R is also called cation-independent M6P receptor (CI-M6PR) because it does not
need ions to bind its ligands. In comparison to their molecular weight, the CD-M6PR (46 kDa)
and the CI-M6PR (250 kDa) are, respectively, called “Small” and “Big” M6P receptor.
Historically, the insulin-like growth factors have been predicted by studying the action of the
pituitary growth hormone (GH) on the growth. GH is a pleiotropic hormone secreted by the
pituitary gland, which acts as a growth factor on bone and muscle tissues, or as a differentiation
factor and a metabolic regulator in liver, fat, and muscle tissues. GH has been historically
proposed to act by using intermediates, the somatomedins, which were able to exert growth
hormone-like effects on the skeletal cartilage and other tissues [4]. Further analyses revealed
two molecules sharing high homology with proinsulin that were consequently called IGF1 and
IGF2 [5, 6].
The insulin-like growth factors 1 and 2 have similar biological effects, but there are never-
theless differences in their expression. In mammals, IGF1 is preferentially expressed after
birth and is almost exclusively produced in the liver, whereas IGF2 is preferentially ex-
pressed in early stages of embryonic and fetal development in many tissues. In adults,
IGF2 is expressed not only in liver but also in other tissues such as the brain (essentially
the meninges) and choroid plexus [7]. IGFs play an important role in the regulation of nor-
mal cell growth and proliferation, or in malignant transformation [8, 9].
The growth hormone’s receptor is a single transmembrane protein sharing similarities with
the prolactin receptor and, to a lesser extent, with some members of cytokine receptor family.
The binding of GH to its receptor induces signaling pathways in most target cells to transduce
hormonal message to the nucleus, which results to activate the transcription of a variety of
genes coding for IGFs or several other proteins such as transcription factors, hormones,
hormone receptors, prolactin receptor, c-fos, cytochrome P450 IIC, and various enzymes.
Several studies reported that M6P/IGF2-R is involved in tumor development in human [9].
This chapter discusses the role of the M6P/IGF2-R in the regulation of growth and its involve-
ment in tumor progression.
2. Structure of the M6P/IGF2-R
The mannose-6-phosphate/insulin-like growth factor 2 is a single-chain transmembrane
protein, of 250–300 kDa that functions as a multifunctional receptor by binding molecules
sharing M6P signals and IGF2 [1, 2]. The M6P/IGF2-R contains 2451 amino acids with a large
extracellular domain made of 2264 residues, a short transmembrane domain of 23 residues,
and a small cytoplasmic domain of 164 residues. The extracellular domain of M6P/IGF2-R
consists of a 40-residue amino acid signal sequence and 15 conserved repeat domains. Each
repeat contains an average length of 150 residues and 13–37% amino acids identity rich in
cysteine residues, which make it highly conserved throughout species, with 60–90% homolo-
gy (Table 1). The repeat number 13 contains a 43-amino acid sequence homologous to the
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collagen-binding domain type 2-region of fibronectin. The mannose-6-phoshate signals bind
to repeats 3 and 9, whereas IGF2 binds to repeat 11 [10–12]. The M6P signals bind to residues
R435 and R1334 localized, respectively, in domains 3 and 9 [10], and the residues (Q392-S431-E460-
Y465) localized in repeat 3 and (Q1292-H1329-E1354-Y1360) localized in repeat 9 play an essential role
in M6P recognition [13] (Figure 1). Further studies showed that domain 5 also steps in
mannose-6-phosphate signal binding. The amino acid residues 1508–1566 localized in repeat
11 are needed for IGF2 binding [14]. Moreover, the affinity of IGF2 binding is enhanced by the
fibronectin type 2-like insert of domain 13, though the biochemical mechanisms of that
enhancement are unknown [9]. However, mannose-6-phosphate receptor does not bind to
IGF2 in oviparous [15].
Human Bovine Chicken Mouse
Human 100 90 60 89
Bovine 90 100 60 87
Chicken 60 60 100 –
Mouse 89 87 – 100
The M6P/IGF2-R amino acid sequences have been compared. Results, expressed in percentage, showed high homology
throughout species including human and varies from 60 to 90%.
Table 1. Sequence homology of M6P/IGF2-R in animals.
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Figure 1. Structure and gene organization of mouse M6P/IGF2 receptor. Numbers in boxes (1–15) symbolize the re-
peat domains. Binding sites are indicated in repeats 3 and 9 (for M6P signals) and in repeat 11 (for IGF2). M6P/IGF2-R
gene consists of 48 exons encoding for the full-length receptor. Amino acid sequences of cytoplasmic domain have
been suggested to interact with adaptor or G proteins.
The M6P/IGF2-R has been shown to be shed from the cell surface and secreted in the culture
medium in Michigan Cancer Foundation 7 (MCF7) cancer cell lines [16] Moreover, other
studies described the M6P/IGF2-R as a circulating protein in rat [17] or in human serum and
urine [18]. Subsequent studies showed that the serum form of M6P/IGF2-R is truncated or
altered in its cytoplasmic domain with a molecular weight of less than 230 kDa [19].
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2.1. Genomic organization and gene imprinting
In mice, M6P/IGF2-R is coded by chromosome 17 [20]. The gene contains 48 exons (Figure 1)
and spreads on 93 kb [21]. M6P/IGF2-R is imprinted in mice. Genomic imprinting is a devel-
opmental gene regulation whereby only one of the parental alleles is expressed [9].
In mice, the M6P/IGF2-R is exclusively expressed from the allele inherited from the mother,
while IGF2 is expressed from the allele inherited from the father [9]. The imprinting of M6P/
IGF2-R is regulated by the intron 2-region in paternal allele, which contains an antisense
transcript mediating the silencing of the paternal M6P/IGF2-R allele. Deletion of that intron 2-
region disrupts the silencing and leads to biallelic expression of M6P/IGF2-R inherited from
the father [22]. Mice inherited from a disrupted M6P/IGF2-R gene from their mother do not
express the receptor in tissues and show malformations in lungs and cardiac muscle. By
contrast, when the same gene is inherited from the father, no abnormality was observed in the
development confirming the paternal imprinting of the M6P/IGF2-R gene [23].
The oppositely imprinting of IGF2 and M6P/IGF2-R genes supposes that M6P/IGF2-R pro-
duced from the mother acts as a scavenger, which neutralizes IGF2 produced from the fa-
ther before it reaches the signaling from IGF1 or insulin receptors to exert its biological
effects [9].
In human, the M6P/IGF2-R gene was previously described to map on chromosome 6q25–27
[20]. Kalscheuer et al. [24] reported that M6P/IGF2-R is not imprinted in human. Others
hypothesized that such an imprinting has been probably lost during evolution [25]. Studies
reporting M6P/IGF2-R imprinting as being polymorphic in human are controversial as the 3’-
untranslated region (3’UTR) polymorphisms used are difficult to amplify and are subject to
misinterpretation.
The consensus retained is that the receptor expression is biallelic in most humans and only
less than 10% of individuals exhibit imprinting of M6P/IGF2-R [26].
3. Functions of the M6P/IGF2-R
The M6P/IGF2-R mainly and continuously circulates and cycles between endomembrane
compartments and cell surface. At a steady state, it is majorly localized in trans-Golgi network
(TGN) and endosomal compartments and poorly present on the plasma membrane.
3.1. Mannose-6-phosphorylated ligand binding and lysosomal enzyme routing
The mannose-6-phosphate signals bind to domains 3 and 9 [10, 12], whereas IGF2 binds to
domain 11 [10, 14]. The binding affinity of M6P/IGF2-R for M6P ligands varies from Kd = 10-10
to 10-6 M and depends on phosphorylated ligand structures [27, 28]. The arginine residues
435R and 1334R, respectively, localized on repeats 3 and 9 are needed for M6P signal binding.
The M6P/IGF2-R is involved in the intracellular trafficking of newly synthesized mannose-6-
phosphorylated lysosomal enzymes from the trans-Golgi network to the late endosomes [29,
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30] and cellular uptake of secreted lysosomal enzyme precursors [31]. Lysosomal enzymes are
recognized by their M6P signals and bind to M6P/IGF2-R. Adaptor proteins AP1 interact with
guanosine triphosphate (GTP)ase adenosine diphosphate (ADP) ribosylation factor (ARF) and
a specific sequence DDSDEDLL localized in the cytoplasmic domain of the M6P/IGF2-R [32,
33]. GTP hydrolysis-released energy is used for clathrin molecule recruitment. Lysosomal
enzymes are then transported, via clathrin-coated vesicles, to acidified endosomal compart-
ments where the low pH (3–5) leads to the dissociation of the enzyme from the receptor [29].
Enzymes are then released to their lysosomal final destination, the lysosomes, whereas the
M6P/IGF2-R are recycled to the cell membrane or headed back to the trans-Golgi network to
accomplish other transport cycles (Figure 2) [29].
Figure 2. Endocytosis and lysosomal enzymes trafficking by the M6P/IGF2-R. Lysosomal enzymes are synthesized in
endoplasmic reticulum and transported in the Golgi where they acquire M6P signals ( ). Mannose-6-phosphorylated
enzymes bind to the M6P/IGF2-R ( ) in the trans-Golgi network and are routed to the late or earlier endosomes. The
receptors bound to secreted enzymes and to IGF2 ( ) at the cell membrane level ( ) are endocytosed and directed to
endosomes. Enzymes and IGF2 are directed to the lysosomes and the receptors ( ) are recycled to the cell membrane.
3.2. Endocytosis of receptors and secreted proenzymes
About 10% of M6P/IGF2-R are found at the plasma membrane level and they can be inter-
nalized and recycled independently of the binding of ligand [34], whereas most of mem-
brane receptors are internalized after the binding of their specific ligand. Secreted
proenzymes are uptaken by the membrane M6P/IGF2-R and the proenzymes/M6P/IGF2-R
complexes are internalized in clathrin-coated vesicles via an interaction between the recep-
tor and adaptor proteins AP2 [33], which recognize cytosolic signals 26YSKV29 of M6P/IGF2-
R [35, 36]. Enzyme/receptor complexes are transported to early endosomes, the enzymes
are then released and transported to late endosomes, then to lysosomes for their matura-
tion into active enzymes, whereas the M6P/IGF2-R are recycled to cell membrane or to the
trans-Golgi network [29].
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3.3. Binding and regulation of IGF2 mitogenic effects
M6P/IGF2-R binds to IGF2 with higher affinity, Kd = 0.1–1 nM [37, 38] and has a lower affinity
for IGF1 [39]. By contrast, it does not bind to insulin [40].
The mitogenic effects of IGF2 are exerted by its binding with lower affinity to the signaling
receptors such as the IGF1 receptor or insulin receptor isoform A [9]. M6P/IGF2-R acts as a
scavenger by mediating internalization and degradation of IGF2 as described previously in
cell cultures including rat adipocytes [41] mouse L-cells [42]. In vivo, studies provide evidence
that M6P/IGF2-R regulates IGF2 circulating and tissue amounts, as shown by gene deletion
experiments in mice [43, 44]. These studies reported that in mice-deficient M6P/IGF2-R, IGF2
levels were two- to threefold increased than wild type. Moreover, the lack of M6P/IGF2-R
increased levels and induces tissue proliferation and hypertrophy that is produced by IGF2
acting on the IGF1 receptor [45].
3.4. Binding to mannose-6-phosphorylated molecules
3.4.1. Transforming growth factor β1
The M6P/IGF2-R is involved in proteolytic activation of the transforming growth factor β1
(TGFβ1), a potent growth inhibitor, that regulates the differentiation and growth in most cell
types [46]. TGFβ1 is a mannose-6-phosphorylated protein synthesized as a single inactive
propreprotein, which is secreted and stored in extracellular matrix. Inactive TGFβ binds to
M6P/IGF2-R and it is then cleaved in mature and active form by extracellular plasmin [47].
This activation mechanism of TGFβ by M6P/IGF2-R has been described in cell culture model
but not in vivo [46, 30]. Moreover, several studies suggested a role of plasmin-mediated
activation of inactive TGFβ following its binding to the M6P/IGF2-R [46, 48, 49].
M6P/IGF2-R is known to bind to domains DII and DII of urokinase receptor [50]. So, other
studies suggest the binding of plasminogen to the complex M6P/IGF2-R/urokinase plasmino-
gen activator receptor, leading to the generation of active plasmin that activates receptor-
bound latent TGFβ [51, 52].
3.4.2. Retinoic acid
Retinoic acid plays an important role in development, cellular metabolism, and regulation of
cell proliferation. The retinoic acid binds to a specific signaling nuclear receptor. Kang et al.
[53] reported that the retinoic acid binds to the cytoplasmic domain of M6P/IGF2-R. Retinoic
acid has been shown to stimulate M6P/IGF2 receptor-mediated internalization of IGF2 and to
increase lysosomal enzymes sorting [30]. M6P/IGF2-R has been proposed to play a role in
mediating retinoid-induced apoptosis/growth inhibition [29].
3.4.3. Leukemia inhibitory factor
M6P/IGF2-R is involved in the internalization and degradation of the cytokine leukemia
inhibitory factor (LIF) leading to its regulation [54].
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3.4.4. Proliferin
Proliferin is a paracrine factor related to prolactin glycoprotein involved in endothelial cells,
angiogenesis during fetal development [55, 56], and a mitogen-regulated protein previously
described in mouse 3T3 fibroblasts [57, 58]. Its signaling pathway suggests a G protein-coupled
receptor [59] but remains unclear.
3.4.5. Prorenin
The prorenin is a proenzyme secreted by juxtaglomerular cells of kidney. The renin catalyzes
the activation of angiotensin I into angiotensin II that regulates blood pressure and extracel-
lular fluid volume [60]. Mannose-6-phosphorylated prorenin [61] binding to M6P/IGF2-R leads
to its internalization and proteolytic activation into renin.
3.4.6. Thyroglobulin
Studies showed that radiolabeled thyroglobulin binds to M6P/IGF2-R [62]. Moreover, thyro-
globulin can be endocytosed by the M6P/IGF2-R but the receptor fails to direct it to the
lysosomes for its degradation in the thyroid gland [63].
4. Does the M6P/IGF2-R interact with G-proteins?
The function of M6P/IGF2-R as a signaling receptor is poorly understood and controversial.
Several studies reported that M6P/IGF2-R lacks intrinsic kinase activity, contrarily to insulin
and IGF1 receptors. The authors suggested that M6P/IGF2-R is coupled to G-protein via a 14-
amino acids sequence (2410RVGLVRGEKARKGK2423) localized in the cytoplasmic domain of the
M6P/IGF2-R (Figure 1) that is similar to the third cytoplasmic loop of G-protein-coupled seven
transmembrane region receptors [64]. Nishimoto et al. [65] showed that IGF2 binds to M6P/
IGF2-R and stimulated calcium channel in mouse Balb/c3T3 cells. Moreover, this action of IGF2
on calcium influx was abolished by Bordetella pertussis toxin or by using antibodies directed
against M6P/IGF2-R, suggesting a G protein-mediated biological effect of M6P/IGF2-R [66].
By contrast, others showed that mice L-cells expressing wild or mutated M6P/IGF2-R and
treated to B. pertussis toxin were capable to block toxin-inhibiting activity. These last results
showed an absence of coupling between M6P/IGF2-R and G-protein [67]. Recent studies using
HEK293 cells suggested a novel mechanism of IGF2-mediated G-protein activation. In that
model, IGF2 binding to M6P/IGF2-R leads to activation of sphingosine kinase and production
of extracellular sphingosine 1-phosphate (S1P), the ligand for G protein-coupled S1P recep-
tors [68]. Others suggested that mannose-6-phosphorylated ligands of M6P/IGF2-R also used
that pathway [59]. However, there is no direct evidence involving the binding of these ligands
and sphingosine kinase activation. Most of biological effects of IGF2 are mediated by IGF1
receptor and insulin receptor [30]. This pathway probably occurs in chicken since IGF2
stimulates protein synthesis and fibroblast mitosis in that species, whereas mannose-6-
phosphate receptor does not bind to IGF2 [15].
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5. Role in human cancers
The study of M6P/IGF2-R in the targeting of newly synthesized mannose-6-phosphorylated
lysosomal enzymes, such as cathepsin D, in human breast cancer lines showed that pro-
cathepsin D is secreted from cancer cell lines, suggesting a possible alteration of M6P/IGF2-R
[69].
Studies on M6P/IGF2-R gene localized on 6q chromosome (6q25–27 region) in human mam-
mary cancers showed losses of heterozygosity (LOH) in 48% of tumors [70, 71].
Further studies showed that M6P/IGF2-R gene exhibited LOH in 30% of breast cancer with
informative mutations in 2/5 of the remaining allele [72]. The LOH phenomenon has been
confirmed in mammary cancers [73] and also described in other human cancers such as
hepatocarcinoma [74] and ovarian cancers [75]. Studies at the protein level in mammary cancer
showed that M6P/IGF2-R levels were significantly lower in cancer cells than in normal cells in
50% of tumors in which the peritumoral normal glands could be quantified in parallel, agreeing
the hypothesis of a tumor suppressor gene for the M6P/IGF2-R [76]. Most of further studies
led on M6P/IGF2-R suggested M6P/IGF2-R as being coded by a tumor suppressor gene [72,
77, 78] and its role as a putative prognostic marker in breast cancers has been hypothesized [76].
6. Conclusion
The M6P/IGF2-R is a multifunctional receptor that is known as binding molecules sharing M6P
signals and IGF2. Further studies showed that it also binds to many other mannose-6-
phosphorylated molecules such as TGFβ, retinoic acid, and so on. The M6P/IGF2-R is a single-
chain membrane receptor consisting of a large extracellular domain of 2264 amino acids
residues organized in 15 repeats, a short transmembrane of 23 amino acids residues, and a
small intracellular domain of 164 residues. The receptor targets newly synthesized mannose-6-
phosphorylated lysosomal enzymes by binding M6P signals on specific sites localized in
repeats 3 and 9 of extracellular domain and transports them from the trans-Golgi network to
lysosomal compartment. The secreted enzymes precursors are internalized by the M6P/IGF2-
R localized on the cell membrane and routed to lysosomes for their maturation. IGF2 binds to
repeat 11 of the receptor and is transported, after internalization, to the lysosomes for its
degradation. IGF2 effects on growth and development are mediated by IGF1 or insulin
receptors, although these receptors bind IGF2 with lower affinity. Consequently, M6P/IGF2-R
is considered as a scavenger that regulates IGF2 levels before it reaches IGF1 receptor to exert
its biological effects on cell proliferation and growth. M6P/IGF2-R would be considered as a
“Garbage Receptor,” since it does not lead to a known biochemical pathway of signal trans-
duction but transports its ligands to lysosomes for degradation, in opposition to “Signaling
Receptor” that induces signal transduction after ligand binding.
The M6P/IGF2-R gene maps on chromosome 6q region and is imprinted in rodents, whereas
its expression is mostly biallelic in human. M6P/IGF2-R gene has been suggested as acting as
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a tumor suppressor since losses of heterozygosity and mutations in the remaining allele have
been frequently described in many human tumors such as mammary, ovarian, and liver
cancers. These previous results are supported by the measures of M6P/IGF2-R at the protein
level showing significant decrease of receptor levels in cancer cells than in normal cells in about
50% of breast tumors, which led to suggest its potential value as a cancer prognostic marker.
Insulin-like growth factor axis has a critical role in mediating fetal and postnatal growth; thus,
alterations in this pathway including changes in the expression of the M6P/IGF2-receptor and
impairments in its function could impact somatic growth. Moreover, genetic evidence clearly
supports a role for IGF2/M6P receptors in organ development and growth.
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